Therapeutic Targets Database
BIDD Pharmainformatics Databases
 
   
   

 

TTD Drug ID: DAP000565

Drug Information
NameCladribine
SynonymsCHEBI:567361; Movectro; CPD000058553; Cladribine [USAN:INN:BAN]; BRN 0624220; cladribinum; SMR000058553; Leustat; DB00242; D01370; 4291-63-8; Chlorodeoxyadenosine; 2-chloro-deoxyadenosine; 2-chloro-6-amino-9-(2-deoxy-beta-D-erythro-pentofuranosyl)purine; cladribina; 2-Chloro-2'-deoxy-beta-adenosine; CHEMBL1619; 2 Chlorodeoxyadenosine; NSC 105014-F; Adenosine, 2-chloro-2'-deoxy; RWJ-26251; CldAdo; NCGC00164384-01; (2R,3S,5R)-5-(6-amino-2-chloropurin-9-yl)-2-(hydroxymethyl)oxolan-3-ol; 2-Chlorodeoxyadenosine; MolPort-005-935-074; UNII-47M74X9YT5; NSC 105014; CID20279; Litak; Cladaribine; NSC-105014; AC-7591; FT-0080707; LS-15109; ADENOSINE, 2-CHLORO-2'-DEOXY-; CL9; MLS000759397; ZINC03798064; 24757-90-2; C10H12ClN5O3.C3H8; D017338; NCGC00022567-05; MLS001077345; RWJ-26251-000; AC1L2FXP; 2-Chloro-6-amino-9-(2-deoxy-beta-D-erythropentofuranosyl)purine; Cladribine; RWJ 26251; 2CdA; HSDB 7564; SAM001246526; 2-CdA; MLS000028377; Mylinax; MLS000028484; 2'-Deoxy-2-chloroadenosine; Cladarabine; MolPort-002-054-532; 2-Chloro-2'-deoxyadenosine; 2ClAdo; S1199_Selleck; HMS2052K13; Leustatin (TN); Leustatin; Leustatin, 2-chlorodeoxyadenosine, Cladribine; Cladribine (JAN/USAN/INN)
IndicationHairy cell leukemia
[ICD9: 202.4   ICD10: C91.4]
Approved    [1]
Structure

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
InChI1S/C10H12ClN5O3/c11-10-14-8(12)7-9(15-10)16(3-13-7)6-1-4(18)5(2-1
7)19-6/h3-6,17-18H,1-2H2,(H2,12,14,15)/t4-,5+,6+/m0/s1
InChIKeyPTOAARAWEBMLNO-KVQBGUIXSA-N
Canonical SMILESC1C(C(OC1N2C=NC3=C2N=C(N=C3N)Cl)CO)O    
Isomeric SMILESC1[C@@H]([C@H](O[C@H]1N2C=NC3=C2N=C(N=C3N)Cl)CO)O
Therapeutic ClassAntineoplastic Agents
CAS NumberCAS 4291-63-8
FormulaC10H12ClN5O3
PubChem Compound IDCID 20279.
PubChem Substance IDSID 163106.
SuperDrug ATC IDL01BB04
SuperDrug CAS ID004291638;
TargetAdenosine deaminaseInhibitor[2][3]
Ref 1Multiple sclerosis: current and future treatment options. Endocr Metab Immune Disord Drug Targets. 2007 Dec;7(4):292-9. To Reference
Ref 2Cladribine: from the bench to the bedside--focus on hairy cell leukemia. Expert Rev Anticancer Ther. 2004 Oct;4(5):745-57. To Reference
Ref 3Cladribine. Ortho Biotech Inc. Curr Opin Investig Drugs. 2001 Dec;2(12):1751-6. To Reference



 

Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.


Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore


All rights reserved.

   
 
 
Computer-aided Drug Design
about BIDD |  databases |  software |  teaching |  research |  links

 

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543